SBTX SkinBioTherapeutics plc
SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development. The company has an agreement with Croda Plc for the development of SkinBiotix as an active ingredient for the skicare and cosmetic industry. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Driffield, the United Kingdom.…
Industry Peers
BiotechnologyKey Statistics
About SkinBioTherapeutics (LON: SBTX)
›
SkinBioTherapeutics (LON: SBTX) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 41 employees.
The shares were at 4.000 GBp on 19 November 2026, down 75.0% over 52 weeks. Its 52-week range is 4.000 GBp to 23.00 GBp, and it trades at the bottom of that range.
Its market capitalisation is 10.37M GBP.
SkinBioTherapeutics reports return on equity of -7.4%, an operating margin of -21.0% and revenue up 37.4% year over year.
It holds more cash than debt, a net cash position of 2.19M GBP. Its Piotroski F-score is 5 out of 9, an average reading of its financial health.